The Industry's foremost leader of anti-venom technologies:

About Anascorp®...

Adverse Reactions

A total of 1534 patients were treated with Anascorp®, ranging from less than one month to 90 years old. The patient population was comprised of 802 males and 732 females. Patients were monitored for signs and symptoms of adverse reactions, including acute hypersensitivity reactions and serum sickness. Follow-up telephone interviews were conducted at 24 hours, 7 days, and 14 days after treatment to assess symptoms suggestive of ongoing venom effect, serum sickness, and any other adverse reactions.

The table below shows the adverse reactions occurring in patients across all clinical trials for Anascorp®. Twenty-seven percent (421/1534) of patients receiving Anascorp® reported at least one adverse reaction.

No patients died or discontinued study participation for severe adverse reactions.
Eight patients were considered to have serum sickness (Type III hypersensitivity); no patient manifested the full serum sickness syndrome. Three patients were treated with systemic corticosteroids and five others received either no treatment or symptomatic therapy.

34 patients experienced a total of 39 severe adverse reactions such as respiratory distress, aspiration, hypoxia, ataxia, pneumonia, and eye swelling. It is not clear whether these adverse reactions were related to Anascorp®, envenomation, or a combination of both.

Anascorp®
Expanded Brochure

  • (Download PDF)

Anascorp®
Cutsheet

  • (Download PDF)

Anascorp®
Package Insert

  • (Download PDF)

Anascorp®
Video
 

  • (Medical Professionals Only)